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Objective: To verify the safety and effectiveness of traditional Chinese red yeast rice-extract (RYR) for
reduction of LDL cholesterol.
Methods: Systematic literature review and meta-analysis. Medline and EMBASE were searched until
November 2014. We selected randomized studies in which RYR with a known content of the active
substance monacolin K was tested against placebo or an active control group. Outcome measures were
the effect of RYR on LDL cholesterol and incidence of adverse reactions with emphasis on liver and
kidney injury and muscle symptoms.
Results: Twenty studies were analyzed. Quality of safety assessment was low in the majority of studies.
RYR lowered LDL cholesterol with 1.02 mmol/L [1.20; 0.83] compared to placebo. Effect of RYR on LDL
was not different from statin therapy (0.03 mmol/L [0.36; 0.41]). The incidence of liver and kidney
injury was 0e5% and the risk was not different between treatment and control groups (risk
difference 0.01 [0.01; 0.0] and 0.0 [0.01; 0.02]).
Conclusions: RYR exerts a clinically and statistically signiﬁcant reduction of 1.02 mmol/L LDL cholesterol.
Only when the mild proﬁle of adverse reactions can be afﬁrmed in studies with adequate methodology
for safety assessment, RYR might be a safe and effective treatment option for dyslipidemia and cardio-
vascular risk reduction in statin intolerant patients.
© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Statins are the most effective agents for improving lipid spec-
trum in order to reduce the risk of atherosclerotic disease [1,2].
While statins are generally well tolerated, a minority of patients
suffers from side effects which diminishes therapy adherence and
limits the full potential of risk reduction [3]. Several patients with a
proven or perceived intolerance to statins and other established
lipid lowering agents use alternative products to inﬂuence their
lipid levels. Also other persons e even without dyslipidemia or
increased cardiovascular risk e use alternative products to lower
their cholesterol [4]. It is a common belief that these ‘natural’ds).
rved.agents do not have side effects. Of these agents, the traditional
Chinese red yeast rice extract (RYR), has been studied in more
detail. In this article we systematically review the evidence on the
potential beneﬁts and risks of RYR in order to determine its suit-
ability in clinical practice.
Muscle symptoms are the major reason for statin intolerance.
However, also non-speciﬁc symptoms such as fatigue, headache or
gastrointestinal symptoms do contribute. The prevalence of statin
intolerance may be up to 10% in clinical practice. Risk factors for
statin intolerance include older age, female sex, renal disease, his-
tory of muscle symptoms and high statin dose [5]. As these risk
factors tend to be exclusion criteria for clinical trials, prevalence of
statin intolerance in trials is lower compared to clinical practice [6].
RYR is well-known in traditional Chinese medicine for its
beneﬁcial effects in cardiovascular disease [7]. RYR consists of
powdered Monascus purpureus fermented rice. Its cholesterol
M.C. Gerards et al. / Atherosclerosis 240 (2015) 415e423416lowering effect is supported by empirical evidence and a plausible
mechanism. Depending on the fermentation conditions of the rice
and the Monascus strains used, HMG-CoA reductase inhibiting
monacolins may be produced as metabolites. Several Monacolin
subtypes were found in RYR products but the most profound sub-
type is monacolin K (MonK) which is identical to lovastatin [8]. In
clinical trials, RYR doses varying from 200 mg to 4800 mg daily
have been studied but monacolin content is not always reported.
Also, commercially available supplements often lack a declaration
of monacolin content [9]. Another concern is the Monascus pur-
pureus metabolite citritin (CTN), which is a mycotoxin that is
known to cause nephrotoxicity [10].
Although RYR is claimed to be a safer alternative to regular
statins, structural similarity with lovastatin implies that similar
adverse reactions can be expected. Indeed anaphylaxis, toxic hep-
atitis and rhabdomyolysis have been associated with the use of RYR
[11e13].
In our study we determined to what extend RYR is an effective
and safe agent for improving lipid proﬁle. We systematically
reviewed and meta-analyzed improvement of lipid proﬁle, as
measured by reduction of low density lipoprotein (LDL)-cholesterol
and safety by assessing the incidence of adverse reactions.Added value to previous meta-analysis on red yeast rice extract
The efﬁcacy of RYR to reduce LDL cholesterol in patients with hyperlipidemia
has been subject to meta-analysis before [14,15]. Our study extends the
knowledge by a systematic and extensive review of evidence on the safety
of RYR.
Fig. 1. Study selection. Flow chart of systematic literature search.2. Methods
We applied methods as recommended by the Cochrane collab-
oration and the report is written in accordance with PRISMA
guidelines [16,17]. The protocol was published online (http://www.
crd.york.ac.uk/prospero, CRD42012003397).
2.1. Search strategy and selection criteria
We conducted a systematic literature search for randomized
studies in which RYR with a known content of MonK was tested
against placebo or an active control group for at least 4 weeks
(Fig. S8). We searched EMBASE and Medline until November 2014.
We did not apply language restrictions.
2.2. Data extraction and assessment of risk of bias
We selected eligible studies subsequently by title, abstract and
full text (MG, CK). Any disagreement was solved by discussion or if
required by the third reviewer. The authors extracted data on study
design, lipid values and adverse reactions by a standardized data
extraction form (MG, RT and HY for Chinese papers, MG and CK for
English papers). Risk of bias was evaluated for all outcome domains.
If lipid values were reported at more than 1 time point during
follow-up, we included the 1st time point from 4 weeks in our
analysis. Adverse reactions of special interest were kidney disease,
liver abnormalities and myopathies. Other adverse reactions were
arranged by organ system. Muscle symptoms were classiﬁed by
symptoms and creatine kinase (CK) level [6].
2.3. Statistical analysis
A meta-analysis was planned on the change in LDL cholesterol,
and on the risk of adverse reactions. Authors were contacted tocomplete missing data. When data on lipid values persisted to be
unavailable we used imputation [17]. Inﬂuence of imputations was
assessed through sensitivity analyses. We separately analyzed
cholesterol lowering efﬁcacy for studies comparing RYR with pla-
cebo or active controls. Statistical heterogeneity was assessed with
the I2-statistic. In case of heterogeneity we investigated potential
causes by performing sensitivity analyses. If heterogeneity could
not be reduced, we applied a random effects model. Excel 2010 and
Review Manager were used for analysis. Results are presented as
mean difference [95% conﬁdence interval] unless otherwise
speciﬁed.3. Results
Our search yielded 286 unique publications. After exclusion of
studies not fulﬁlling selection criteria, we analyzed 36 publications
on 20 studies (Fig. 1) [18e53]. Twenty-six papers were written in
English and others were Chinese. The studies contained 6663
subjects in total, of which a large proportion was included in the
Chinese Coronary Secondary Prevention Study (CCSPS)
[21,22,33e37,40,41,48,53]. The CCSPS aimed to demonstrate a
reduction in cardiovascular events and had a follow-up duration of
3.5 years. All other studies, which had surrogate parameters as
primary outcome had a shorter follow-up (2e24 months). Five
studies were conducted in Europe and North America and 14
studies were conducted in China. One study included patients in
North America as well as China [42,43]. Three studies compared
RYR to statin therapy, 13 studies compared RYR to inactive treat-
ment and in 4 studies RYR was compared to a non-statin active
control group (Table 1).
Dose of RYR varied from 1200 mg to 4800 mg per day, con-
taining 4.8 mge24 mg MonK. Four studies reported the constitu-
ents of RYR including different monacolin subtypes and possible
toxins. In these studies, the MonK subtype was 57e75% of the total
monacolin content. Six studies reported the MonK content without
further speciﬁcation and other studies referred to the RYR manu-
facturer. Citrinin concentration was determined in 3 studies and
varied from <0.05 mg to <18 mg per daily dose.
Table 1
Characteristics of included studies.
Study þ Reference Country Participants Interventions Follow-up
(weeks)a
Masking Primary outcome Funding
Main eligibility
criteria
Age e mean (SD) Sex e % male
Becker 2009
[18,19]
US DL, statin
intolerance (n¼ 62)
61 (8.5) 36 RYR 3600 mg (6.1 mgMonK) vs.
placebo
24 (12) Double-blind Lipid proﬁle and RYR
tolerability
Commonwealth of
Pennsylvania (unrestricted)
Bogsrud 2010 [20] Norway DL, DM2 (n ¼ 42) e e 2400 mg RYR (4.8 mgMonK) vs.
placebo
16 (6) Double-blind Lipid proﬁle Pharmalogica AS
(Scandinavian distributor of
RYR)
CCSPS 2008
[21,22,33e
37,40,41,48,53]
China CHD (n ¼ 4870) 58.9 (10) 82 RYR 1200 mg (11.6 mg MonK)
vs. placebo
168 Double-blind Reduction of
cardiovascular events
Chinese National Scientiﬁc
and Technological Projects,
WPU
Fan 2010 [23] China Non-alcoholic
steatosis, DL
(n ¼ 84)
54.5 (10) 49 RYR 1200 mg (10 mg MonK) vs.
polyenylphosphatidylcholine
1.4 g
24 (12) No masking Inﬂammatory factors
(TNF-a, IL-6)
Unknown
Gong 2010 [24] China Hypertension, LVH
(n ¼ 60)
57.7 (7.9) 50 RYR 1200 mg (10 mg
MonK) þ valsartan vs. valsartan
onlyb
104 No masking Left ventricular mass &
heart rate turbulence
Unknown
Halbert 2010 [25] US DL, statin
intolerance (n¼ 43)
62.6 (8) 26 RYR 4800 mg (MonK 9.96 mg)
vs. pravastatin 40 mg
24 Double-blind Myalgia Commonwealth of
Pennsylvania
(unrestricted), Center for
CAM, National Institute on
Aging
Heber 1999 [26] US DL (n ¼ 88) 61.5 (9) 56 2400 mg RYR (4.8 mgMonK) vs.
placebo
12 (6) Double-blind Lipid proﬁle Pharmanexc (unrestricted).
Heber is cochair of
Pharmanex medical
advisory board.
Hu 2006 [27] China CHD (n ¼ 50) 54.7 (4.25) 62 1200 mg RYR (13.5 mg total
monacolins) vs. placebob
6 Double-blind Lipid proﬁle and CRP Unknown
Huang 2006 [29] China CHD (n ¼ 112) 61.2 (16.7) 52 RYR 1200 mg (10 mg MonK) vs.
probucol 1000 mg
8 No masking Vascular endothelial
function and redox
state of vascular
endothelium
Sichuan Science and
Technology Department
Jian 1999 [30] China DL (n ¼ 91) 57.3 (10.8) 63 1200 mg RYR (MonK 10 mg) vs.
gemﬁbrozil 1200 mg
8 No masking Lipid proﬁle,
thromboxane A-2 and
prostacyclin
Unknown
Keithley 2002 [31] US HIV, DL (n ¼ 14) 42.5 (7.8) 75 RYR 2400 mg (MonK 4.8 mg) vs.
placebo
8 Double-blind Lipid proﬁle, safety
(plasma HIV RNA, CD4þ
cells, liver function
tests)
Pharmanexc provided study
medication
Kou 1997 [32] China DL (n ¼ 108) 55.8 62 RYR 1200 mg (10 mg MonK) vs.
simvastatin 10 mg vs. placebo
8 (4) No masking Change of lipid proﬁle Unknown
Lin 2005 [28,38] Taiwan DL (n ¼ 79) 46.4 (10) 57 RYR 1200 mg (MonK 11.4 mg)
vs. placebo
8 (4) Double-blind Lipid proﬁle and safety Y&B pharmaceuticals
(unrestricted).
Liu 2011 [39] China DL, carotid
atherosclerosis
(n ¼ 40)
58.2 (5.7) 60 RYR 1200 mg (10 mg MonK) vs.
lovastatin 20 mgb
24 No masking Lipid proﬁle and carotid
intima-media
thickness.
department of TCM
Administration
Roth 2013 [42,43] US &
China
DL (n ¼ 116) 56.7 (10.8) 26 RYR 2400 mg (24 mg MonK) vs.
RYR 1200 mg (12 mg MonK) vs.
placebo
12 Double-blind Lipid proﬁle WPU and Luye Pharma
Group, China. 6/20 authors
are employees of Luye
Pharma group
Wang 1997 [44] China DL (n ¼ 502) 56.1 (0.6) 59 1200 mg (2.4 mg MonK) vs.
jiaogulan (TCM)
8 (4) Patients
blinded
Lipid proﬁle 2/11 authors are employees
of Pharmanex and 2/11
authors are employees of
WPU.
Wang 2004 [45] China CHD (n ¼ 105) 59.9 (8.8) 65 RYR 1200 mg (10 mg MonK) vs.
noneb
12 No masking Unknown
(continued on next page)
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M.C. Gerards et al. / Atherosclerosis 240 (2015) 415e4234183.1. Quality of evidence
The majority of study reports did not contain sufﬁcient infor-
mation to judge all potential sources of bias. Risk of bias was
evident in the assessment of adverse reactions which could have
led to an underestimation of the incidence of adverse reactions in
the RYR group (Fig. S1).
3.1.1. Quality of safety assessment in included studies
Liver abnormalities and kidney injury were assessed in 14 and 8
studies respectively. Seven studies reported the incidence of
intervention-associated increased liver transaminases whereas 5
studies reported average levels of transaminases. Three studies did
not report numerical outcomes although liver transaminases were
assessed. Three studies reported incident cases of kidney injury and
2 studies reported average creatinine before and after treatment.
Four studies reported no numerical outcomes for kidney injury
although it was assessed. All but 1 study did not report cut-off
values for laboratory parameters of kidney or liver injury [38].
Muscle symptoms were assessed in 10 studies through CK and 2
studies also included anticipated symptom assessment through a
validated questionnaire. Nine studies reported incident cases of
muscle symptoms and 2 studies reported average CK before and
after treatment.
Seventeen studies assessed other adverse reactions. Three
studies roughly described the way symptoms were assessed and
this was not described in all other studies. Four studies reported all
adverse reactions and three studies only reported adverse reactions
that led to discontinuation of study treatment. Two studies did not
present numerical data and in 8 studies criteria for reporting events
were not speciﬁed. An overview on the methodology and reporting
of safety outcomes is given in Table 2.
3.2. Efﬁcacy of RYR for improvement of lipid proﬁle
The effect of RYR on lipid proﬁle was moderate to considerable
heterogeneous. We performed sensitivity analyses on studies with
different doses of RYR and MonK, different durations of follow-up
and different ethnic study populations. Heterogeneity remained
and we performed all meta-analyses on lipid proﬁle by random-
effect analysis.
3.2.1. RYR versus inactive control treatment
RYR was more effective for reduction of LDL cholesterol
compared to placebo (Fig. 2). LDL decrease in the population
treated with RYR varied from 0.5 to 1.59 mmol/L with a pooled
estimate of 1.02 mmol/L [1.20; 0.83] compared to placebo.
Regarding changes in other lipid parameters, RYR resulted in a
stronger reduction of total cholesterol compared with placebo
(1.0 mmol/L [1.23; 0.77]). There was a small increase in high
density lipoprotein (HDL) cholesterol of 0.07 mmol/L [0.03; 0.11]
and a 0.26 mmol/L [0.35; 0.17] decrease in triglycerides
(Figs. S2eS4).
3.2.2. RYR versus regular statin therapy
Three studies comparing RYR with MonK 10 mg daily to regular
statin therapy (pravastatin 40 mg, simvastatin 10 mg, lovastatin
20 mg) did not show a signiﬁcant difference between the in-
terventions. Themean difference of change scores were 0.03mmol/
L [0.36; 0.41] for LDL (Fig. 2) and 0.05 mmol/L [0.28; 0.18] for
total cholesterol (Fig. S2).
3.2.3. RYR versus non-statin active control treatment
LDL reduction in RYR groups was 0.52 mmol/L [0.9; 0.14]
higher than the control group (Fig. 2). One study compared RYR to
Table 2
Method and reporting of safety assessment in included studies. Method of evaluation andway of reporting for the 3 safety outcomes of interest and other adverse reactions and
patient reported symptoms. All evaluations were done at baseline and end of study unless reported otherwise.
Study Kidney disease Liver disease Muscle symptoms Patient reported symptoms
Becker Method Not reported/not assessed AST and ALT CK, muscle symptoms (Brief
Pain Inventory, validated) and
muscle weakness
(dynamometry, validated).
Not reported
Reporting None Means (BL, 12 wk, EOS). Means (BL, 12 wk, EOS).
Incident cases of intolerable
persistent myalgia.
Incident cases
Bogsrud Method Creatinine and BUN (BL,
6 wk, EOS)
AST, ALT, GGT (BL, 6 wk, EOS) CK (BL, 6 wk, EOS). No
anticipated symptom
assessment.
Not reported
Reporting No numerical data No numerical data No numerical data/1incident
case
Incident cases, speciﬁed by
group and type.
CCSPS Method BUN and Creatinine every 6
months
ALT and AST every 6 months CK every 6 months. No
anticipated symptom
assessment.
Assessed, not speciﬁed.
“Symptoms were registered.”
Reporting Incident cases (subgroup,
n ¼ 2704 [37])
See column 'kidney disease' See column 'kidney disease' See column 'kidney disease'
Fan Method Not reported/not assessed AST, ALT, GGT, cholinesterase. CK. No anticipated symptom
assessment.
Assessed, not speciﬁed.
Reporting None Means (BL, 12 wk, EOS). Means in treatment group (BL,
12 wk, EOS).
1 incident case (no other
obvious AEs were found)
Gong Method Renal function every 3
months
Liver function every 3 months Not reported/not assessed Assessed every 6 months, not
speciﬁed.
Reporting No numerical data No numerical data None Incident cases (few)
Halbert Method Not reported/not assessed Assessment of liver-associated
enzymes
CK, muscle symptoms (Brief
Pain Inventory, validated) and
muscle weakness
(dynamometry, validated).
Not reported
Reporting None Outcome were assessed in t-
test but numerical result is not
reported
Incidence of different grades of
myalgia. Means of muscle
strength.
Incidence of adverse reactions
categorized by type, per
treatment group.
Heber Method BUN ALT, AST, GGT, LDH Not reported/not assessed Not reported
Reporting Means and incident cases Means and incident cases None Incident cases
Hu Method Not reported/not assessed Not reported/not assessed CK, no anticipated symptom
assessment.
Not reported
Reporting None None Incident cases None
Huang Method Not reported/not assessed Not reported Not reported/not assessed Not reported
Reporting None Incident cases None Incident cases
Jian Method Not reported/not assessed Not reported/not assessed Not reported/not assessed Not reported/not assessed
Reporting None None None None
Keithley Method Not reported/not assessed Albumin, total and direct
bilirubin, ALP, AST, ALT (BL,
2 wk, EOS).
Not reported/not assessed Active questioning on any
symptoms (2 wk, EOS).
Reporting None Change in means from baseline
to EOS.
None No numerical data
Kou Method Creatinine and BUN (BL,
4 wk, EOS).
Liver palpation, ALT CK (BL, 4 wk, EOS). No
anticipated symptom
assessment.
Not reported
Reporting Incident cases Incident cases Incident cases Incident cases
Lin Method Not reported/not assessed AST, ALT CK (BL, 4 wk, EOS). No
anticipated symptom
assessment.
Assessment of severity and
relation to study agent of any
AE
Reporting None Incident cases Incident cases Incident cases
Liu 2011 Method Creatinine and BUN ALT Not reported/not assessed Not reported/not assessed
Reporting No numerical data Incident case (1) None Incident cases
Roth Method Not reported/not assessed ALT (BL, 4 and 8 wk, EOS) CK (BL, 4 and 8 wk, EOS). No
anticipated symptom
assessment.
Open-ended questioning on
any AE (4 and 8 wk, EOS).
Reporting None Incident cases Incident cases Incident cases
Wang 1997 Method Creatinine and BUN ALT CK Assessed (4 wk, EOS), not
speciﬁed.
Reporting Not reported Incident cases Incident cases Incident cases
Wang 2004 Method Not reported/not assessed Not reported/not assessed Not reported Not reported/not assessed
Reporting None None Incident cases Incident cases
Wu Method Not reported/not assessed Not reported/not assessed Not reported/not assessed Not reported/not assessed
Reporting None None None Incident cases
Yang Method Creatinine and BUN AST, ALT Not reported/not assessed Assessed, not speciﬁed.
Reporting Means (BL, 4 and 12 wk,
EOS).
Means (BL, 4 and 12 wk, EOS). None No numerical data
Zhao Method Not reported/not assessed Not reported/not assessed Not reported/not assessed Not reported/not assessed
Reporting None None None None
Abbreviations: BL ¼ baseline. wk ¼ weeks. EOS ¼ end of study. AE ¼ adverse event. ALP ¼ alkaline phosphatase. ALT ¼ alanine transaminase. AST ¼ aspartate transaminase.
BUN ¼ blood urea nitrogen. CK ¼ creatine kinase. GGT ¼ gamma glutamyl transpeptidase. LDH ¼ lactate dehydrogenase.
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Fig. 2. Effect of red yeast rice (RYR) extract compared to inactive control treatment, statin therapy and non-statin active control treatment on change in LDL cholesterol from
baseline.
M.C. Gerards et al. / Atherosclerosis 240 (2015) 415e423420gemﬁbrozil and 3 other studies treated the control group with
herbal agents. In the study comparing treatment with RYR to
gemﬁbrozil, the gemﬁbrozil group had a greater improvement of
triglycerides and RYR was beneﬁcial on all other lipid parameters
(Fig. S4).3.3. Safety of red yeast rice extract
3.3.1. Kidney injury and elevation of liver transaminases
The incidence of cases of liver abnormalities and kidney injury
was between 0 and 5% in both RYR and control groups. We did not
observe a signiﬁcant effect of RYR on the risk of liver abnormalities
or kidney injury (Figs. S5eS6). Average level of liver transaminases
in the RYR group decreased in all 5 studies inwhich it was reported.3.3.2. Muscle symptoms
The reported incidence of developing muscle symptoms was
0e23.8% for the population treated with RYR, versus 0e36% in the
control groups. Rhabdomyolysis or myopathy with increased
CK > 10 times upper limit of normal was not observed in any of the
studies. The risk difference between RYR and control groups for
myalgia was 0.00 [0.01, 0.01] (Fig. S7).
One study compared myopathies between subjects treated with
RYR versus pravastatin in a population selected for its increased risk
on developing adverse reactions [25]. In this study the risk for
developing muscle symptoms in the RYR group was 0.13 [0.40;
0.15) lower compared to patients in the pravastatin group.3.3.3. Patient reported symptoms
Other adverse reactions and patient reported symptoms were
classiﬁed by organ system (Table 3). The overview is limited by the
fact that in most studies the methods for evaluating, deﬁning and
reporting adverse reactions were unclear and the risk of bias was
often high. Four studies that reported all adverse reactions found an
incidence of 30e76% of mild adverse reactions. In the other studies
for which the criterion was unclear only 0e9% of subjects experi-
enced an adverse reaction. Patients mainly complained of gastro-
intestinal and musculoskeletal symptoms. Besides, patients on
RYR and controls reported nonspeciﬁc complaints (22/199 vs. 33/
199).
4. Discussion
Our study shows that RYR reduces LDL cholesterol and suggests
that the rate and type of adverse reactions are mild. Patients with
an increased risk of adverse reactions on statins sometimes do
tolerate RYR. However, the majority of studies did not contain
enough data on safety.
The LDL lowering effect of 1.02 mmol/L compared to placebo is
relevant since in a recent meta-analysis, a corresponding cardio-
vascular risk reduction of 15e20 % was described [54]. Especially
for statin-intolerant patients, where alternatives for regular statin
therapy to achieve LDL reduction are scarce, RYR can contribute to
signiﬁcant reduction in cardiovascular events.
In our analysis the average dose of MonK was 10.8 mg per day.
Based on studies in which all monacolin subtypes were analyzed,
Table 3
Adverse reactions and patient reported symptoms. Absolute incidence of categorized adverse reactions in RYR/control group.*hypertensive subgroup (n ¼ 2704, results were
not reported on full population).
RYR/control
➔
Sum Becker Bogsrud CCSPS* Fan Gong Halbert Heber Huang Kou Lin Liu Roth Wang
1997
Wang
2004
Wu
Gastro-intestinal Diarrhea 7/1 1/0 2/0 0/0 1/0 0/0 2/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 1/0 0/0
GI discomfort 42/19 0/0 1/1 10/3 0/0 3/1 3/0 0/0 0/2 2/1 0/1 1/0 15/10 5/0 2/0 0/0
Other GI 2/0 0/0 1/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 1/0
Subtotal 51/20 1/0 4/1 10/3 1/0 3/1 5/0 0/0 0/2 2/1 0/2 1/0 15/10 5/0 3/0 1/0
Musculo-skeletal Arthralgia 14/7 0/0 0/0 0/0 0/0 0/0 1/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Weakness 1/2 0/0 0/0 0/0 0/0 0/0 1/2 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Subtotal 15/9 0/0 1/0 0/0 0/0 0/0 7/9 1/0 0/0 0/0 0/0 0/0 0/0 6/0 0/0 0/0
Laboratory LDH 1/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 1/0 0/0 0/0 0/0 0/0 0/0
Leukocytosis 2/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 2/0 0/0 0/0 0/0
Leukopenia 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0
Hyperglycemia 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1
Subtotal 3/2 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 1/1 0/0 2/0 0/0 0/0 0/1
Infectious Inﬂuenza 1/0 0/0 1/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Urinary tract 9/4 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 9/4 0/0 0/0 0/0
Pneumonia 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Subtotal 10/5 0/0 1/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 9/4 0/0 0/0 0/0
Immunologic Rash 0/2 0/0 0/0 0/0 0/0 0/1 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Alopecia 2/0 0/0 0/0 0/0 0/0 0/0 2/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Allergic 5/2 0/0 0/0 3/2 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 2/0
Subtotal 7/4 0/0 0/0 3/2 0/0 0/1 2/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 2/0
General Dizziness 2/2 1/0 0/0 0/0 0/0 0/0 0/2 0/0 0/0 0/0 0/0 0/0 0/0 1/0 0/0 0/0
Malaise 1/0 0/0 1/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Fatigue 3/4 0/0 0/0 0/0 0/0 0/0 0/3 0/0 0/0 3/1 0/0 0/0 0/0 0/0 0/0 0/0
Subtotal 6/6 1/0 1/0 0/0 0/0 0/0 0/5 0/0 0/0 3/1 0/0 0/0 0/0 1/0 0/0 0/0
CNS Headache 5/5 0/0 0/0 0/0 0/0 0/0 2/2 0/1 0/0 0/0 0/0 0/0 3/2 0/0 0/0 0/0
Cardiovascular QT prolongation 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Uncontrolled
hypertension
0/2 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/2
Edema 2/0 0/0 0/0 2/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Erectile
dysfunction
0/3 0/0 0/0 0/3 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Subtotal 2/6 0/0 0/0 2/3 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/2
Miscellaneous Breast cancer 1/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 1/0 0/0 0/0 0/0 0/0 0/0
Unspeciﬁed 22/29 0/0 0/0 3/3 0/0 0/0 0/0 0/0 0/0 0/0 17/25 0/0 2/1 0/0 0/0 0/0
Subtotal 23/29 0/0 0/0 3/3 0/0 0/0 0/0 0/0 0/0 0/0 18/25 0/0 2/1 0/0 0/0 0/0
The values in bold denote the total amount of cases for each adverse event (as opposed to the results in the individual studies).
M.C. Gerards et al. / Atherosclerosis 240 (2015) 415e423 421the total monacolin content is expected to be 6.1e8.1 mg higher. It
is likely that some of these other monacolin subtypes contribute to
HMG-CoA reductase inhibition and reduction of LDL cholesterol,
although unknown to which extent. Other studies evaluating the
efﬁcacy of 10e20 mg of lovastatin resulted in an equivalent LDL
reduction of 1.01e1.8 mmol/L [55].
Sometimes it is said that other non-statin components such as
unsaturated fatty acids might explain the LDL lowering effect of
RYR [56]. However, when taking into account the total monacolin
content e which is probably underestimated when looking at
MonK only e RYR produces the same magnitude of LDL reduction
compared to regular statin therapy. RYR consists of carbohydrates
(75%), monacolins (10e15%), fatty acids (1.5%), pigments (including
citrinin) and trace elements [56]. In our conviction, it is unlikely
that non-statin RYR components in the quantity present, exert a
signiﬁcant effect on LDL cholesterol or cardiovascular health via
other pathways.
The low incidence of adverse reactions that we observed is
probably an underestimation of the true incidence, due to a poor
methodology of safety evaluation in the majority of studies.
Furthermore, most studies were not endowed to make a judgment
on the occurrence of adverse reactions in the general population:
by excluding elderly people and various comorbidities, patients
vulnerable for adverse reactions were systematically excluded.
However, incidence of liver and kidney injury was assessed in 7 and
3 studies respectively and was similar to control groups. Two
studies deﬁned and assessed muscle symptoms clearly and found
an acceptable rate of adverse reactions in statin intolerant patients
[18,25]. Tolerance of RYR in these patients might be explainedthrough a lower statin content of RYR. One study compared RYR
containing 9.96 mg lovastatin to pravastatin 40 mg daily. While the
correlation between statin dose and LDL reduction is generally low,
adverse effects are more prevalent at higher statin doses [6].
Our results do not suggest that RYR results in different adverse
reactions than the usual statin-associated adverse reactions. This
conclusion is supported by case reports on RYR related adverse
reactions, which describe mainly cases of usual statin-related
adverse reactions. We investigated potential harm through the
mycotoxin citrinin but we did not ﬁnd an increased risk of kidney or
liver injury. However, since RYR is sold as a dietary supplement, a
registration study with thorough analysis of all possible adverse
reactions has never been performed. For conventional statin ther-
apy, incidence of muscle symptoms, liver and kidney damage has
been analyzed over 45,000e290,000 person years [57e59].
Besides efﬁcacy and safety, suitability of RYR in clinical practice
is limited by ﬁnancial and legal issues. RYR containing 10 mgMonK
daily, is 3e12 times more expensive compared to regular brand
HMG-CoA reductase inhibitors [60]. Since RYR is a food supple-
ment, there are no uniform standards for its production and
monacolin content. The US Food and Drug Administration prohibits
RYR containing MonK but as RYR supplements are not registered
this prohibition is not maintained adequately [61]. European
regulation is limited to restrictions on health beneﬁts that may be
claimed through using food supplements. Within this framework,
the European Food Safety Authority investigated and conﬁrmed a
beneﬁcial effect of MonK on lipid spectrum [62]. However, since the
monacolin concentration in over-the-counter available RYR is often
uncertain, this claim may not be extrapolated to all RYR products.
M.C. Gerards et al. / Atherosclerosis 240 (2015) 415e423422A strength of our study is the detailed analysis of adverse re-
actions that could be attributed to RYR. RYR has been subject to
meta-analysis before and these analyses resulted in comparable
effects on lipid proﬁle but none of the studies thoroughly assessed
the safety of RYR [14,15]. Aweakness of this meta-analysis were the
differences in design and primary outcomes of the studies
analyzed. The differences in the objectives of included studies led to
differences in their designs, and probably resulted in the high level
of heterogeneity for our primary outcome.
5. Conclusion
In conclusion, RYR exerts a 1.02mmol/L reduction of low density
lipoprotein cholesterol. The beneﬁcial effect was achieved with
10.4 mg (±4.5) MonK daily. Although safety analysis of RYR was not
a priority of the majority of studies analyzed, the incidence of
kidney injury (evaluated in 2895 subjects), liver injury (evaluated
in 2895 patients) and muscle symptoms (evaluated thoroughly in
105 patients) was found to be an acceptable rate.
To determine the suitability of RYR in clinical practice, moni-
toring of adverse reactions should become a priority of future trials
which need to include patients at risk for statin intolerance. Only
when the mild proﬁle of adverse reactions can be afﬁrmed, RYR
might be a safe and effective treatment option for dyslipidemia and
cardiovascular risk reduction.
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